238 related articles for article (PubMed ID: 23845105)
21. Coumestrol suppresses proliferation of ES2 human epithelial ovarian cancer cells.
Lim W; Jeong W; Song G
J Endocrinol; 2016 Mar; 228(3):149-60. PubMed ID: 26698565
[TBL] [Abstract][Full Text] [Related]
22. Small molecule modulators targeting protein kinase CK1 and CK2.
Qiao Y; Chen T; Yang H; Chen Y; Lin H; Qu W; Feng F; Liu W; Guo Q; Liu Z; Sun H
Eur J Med Chem; 2019 Nov; 181():111581. PubMed ID: 31400711
[TBL] [Abstract][Full Text] [Related]
23. p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.
Schneider CC; Hessenauer A; Montenarh M; Götz C
Prostate; 2010 Feb; 70(2):126-34. PubMed ID: 19760628
[TBL] [Abstract][Full Text] [Related]
24. Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
Hundsdörfer C; Hemmerling HJ; Götz C; Totzke F; Bednarski P; Le Borgne M; Jose J
Bioorg Med Chem; 2012 Apr; 20(7):2282-9. PubMed ID: 22377675
[TBL] [Abstract][Full Text] [Related]
25. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor.
Jin CH; Jun KY; Lee E; Kim S; Kwon Y; Kim K; Na Y
Bioorg Med Chem; 2014 Sep; 22(17):4553-65. PubMed ID: 25131958
[TBL] [Abstract][Full Text] [Related]
26. Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.
Gratz A; Kuckländer U; Bollig R; Götz C; Jose J
Mol Cell Biochem; 2011 Oct; 356(1-2):83-90. PubMed ID: 21750981
[TBL] [Abstract][Full Text] [Related]
27. Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton.
Kramerov AA; Golub AG; Bdzhola VG; Yarmoluk SM; Ahmed K; Bretner M; Ljubimov AV
Mol Cell Biochem; 2011 Mar; 349(1-2):125-37. PubMed ID: 21125314
[TBL] [Abstract][Full Text] [Related]
28. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel CK2 leads by cross-docking based virtual screening.
Sun H; Wu X; Xu X; Jiang Z; Liu Z; You Q
Med Chem; 2014; 10(6):628-39. PubMed ID: 24286395
[TBL] [Abstract][Full Text] [Related]
30. Salicylaldehyde derivatives as new protein kinase CK2 inhibitors.
Prudent R; López-Ramos M; Moucadel V; Barette C; Grierson D; Mouawad L; Florent JC; Lafanechère L; Schmidt F; Cochet C
Biochim Biophys Acta; 2008 Dec; 1780(12):1412-20. PubMed ID: 18674590
[TBL] [Abstract][Full Text] [Related]
31. Resorufin: a lead for a new protein kinase CK2 inhibitor.
Sandholt IS; Olsen BB; Guerra B; Issinger OG
Anticancer Drugs; 2009 Apr; 20(4):238-48. PubMed ID: 19177021
[TBL] [Abstract][Full Text] [Related]
32. A novel class of selective CK2 inhibitors targeting its open hinge conformation.
Dalle Vedove A; Zonta F; Zanforlin E; Demitri N; Ribaudo G; Cazzanelli G; Ongaro A; Sarno S; Zagotto G; Battistutta R; Ruzzene M; Lolli G
Eur J Med Chem; 2020 Jun; 195():112267. PubMed ID: 32283296
[TBL] [Abstract][Full Text] [Related]
33. Biochemical and cellular mechanism of protein kinase CK2 inhibition by deceptive curcumin.
Cozza G; Zonta F; Dalle Vedove A; Venerando A; Dall'Acqua S; Battistutta R; Ruzzene M; Lolli G
FEBS J; 2020 May; 287(9):1850-1864. PubMed ID: 31661600
[TBL] [Abstract][Full Text] [Related]
34. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells.
Yao K; Youn H; Gao X; Huang B; Zhou F; Li B; Han H
Prostate; 2012 Sep; 72(13):1423-30. PubMed ID: 22290244
[TBL] [Abstract][Full Text] [Related]
35. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
[TBL] [Abstract][Full Text] [Related]
36. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition.
Battistutta R
Cell Mol Life Sci; 2009 Jun; 66(11-12):1868-89. PubMed ID: 19387547
[TBL] [Abstract][Full Text] [Related]
37. N-substituted Indole-2 and 3-carboxamide derivatives as inhibitors of human protein kinase CK2: in vitro assay and molecular modelling study.
Olgen S; Gratz A; Kurt ZK; Jose J
Acta Chim Slov; 2013; 60(3):628-35. PubMed ID: 24169717
[TBL] [Abstract][Full Text] [Related]
38. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
[TBL] [Abstract][Full Text] [Related]
39. Kinase CK2 inhibition: an update.
Cozza G; Pinna LA; Moro S
Curr Med Chem; 2013; 20(5):671-93. PubMed ID: 23210774
[TBL] [Abstract][Full Text] [Related]
40. Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors.
Kufareva I; Bestgen B; Brear P; Prudent R; Laudet B; Moucadel V; Ettaoussi M; Sautel CF; Krimm I; Engel M; Filhol O; Borgne ML; Lomberget T; Cochet C; Abagyan R
Sci Rep; 2019 Nov; 9(1):15893. PubMed ID: 31685885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
